Search
Azacitidine
go.drugbank.com/drugs/DB00928ApprovedInvestigationalIn January 2007, the FDA approved the intravenous administration of azacitidine. … [A1415] The use of oral azacitidine for the treatment of AML in patients in complete remission was approved by the FDA in September 2020.[L35335]
Dimenhydrinate
go.drugbank.com/drugs/DB00985ApprovedInvestigational[L32985] The antiemetic properties of dimenhydrinate are primarily thought to be produced by diphenhydramine's antagonism of H1 histamine receptors in the vestibular system[A1540] while the excitatory … effects are thought to be produced by 8-chlorotheophylline's adenosine receptor blockade.
Nevirapine
go.drugbank.com/drugs/DB00238ApprovedInvestigationalStructurally, nevirapine belongs to the dipyridodiazepinone chemical class.
Categories: Antivirals used in combination for the treatment of HIV infectionsSynonyms: 11-cyclopropyl-5,11-dihydro-4-methyl-6H-dipyrido(3,2-b:2',3'-e)(1,4)diazepin-6-oneCariprazine
go.drugbank.com/drugs/DB06016ApprovedInvestigationalCariprazine gained its first global approval in the US in September 2015 [A3941] and was later approved by Health Canada in April 2022. … [L41670] It is currently used to treat schizophrenia, and manic or mixed episodes and depressive episodes associated with bipolar I disorder.[L41655,L40198]
Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin SyndromeBepridil
go.drugbank.com/drugs/DB01244ApprovedWithdrawnIt is no longer marketed in the United States, as it has been implicated in causing ventricular arrhythmias (ie. Torsade de pointes). … The drug produces significant coronary vasodilation and modest peripheral effects. It has antihypertensive and selective anti-arrhythmia activities and acts as a calmodulin antagonist.
Trilaciclib
go.drugbank.com/drugs/DB15442ApprovedInvestigationalTrilaciclib, or G1T28, is a CDK4 and CDK6 inhibitor, indicated to reduce the incidence of chemotherapy induced myelosuppression in patients before topotecan-containing or platinum and etoposide-containing … [L31828] CDK4 and CDK6 inhibitors have been investigated since the mid 1990s for their use in tumorigenesis and chemotherapy.[A229323] Trilaciclib was first described in the literature in 2016.
Lumiracoxib
go.drugbank.com/drugs/DB01283ApprovedWithdrawnOn August 11, 2007, Australia's Therapeutic Goods Administration (TGA, the Australian equivalent of the FDA) cancelled the registration of lumiracoxib in Australia due to concerns that it may cause liver … New Zealand and Canada have also followed suit in recalling the drug.
Leuprolide
go.drugbank.com/drugs/DB00007ApprovedInvestigationalUnlike the endogenous decapeptide GnRH, leuprolide contains a single D-amino acid (D-leucyl) residue, which helps to increase its circulating half-life from three to four minutes to approximately three … [A203222] As a GnRH mimic, leuprolide is capable of binding to the GnRH receptor (GnRHR) and inducing downstream modulation of both gonadotropin hormone and sex steroid levels.
Products: TOZ ICEREN SIRINGA VE COZUCU ICEREN SIRINGA, 1 ADET, TOZ ICEREN SIRINGA VE COZUCU ICEREN SIRINGA, 1 ADETFosfomycin
go.drugbank.com/drugs/DB00828ApprovedInvestigational[A229338,A230348] It may also be produced synthetically and is commercially available as the disodium salt for intravenous administration and as the calcium or trometamol salt for oral administration. … [A230348] As such there is great interest in exploring the usefulness of fosfomycin for indications beyond the treatment of UTIs.[A230353,A230358]
Ceftriaxone
go.drugbank.com/drugs/DB01212ApprovedInvestigationalthe convenience of daily or twice-daily dosing. … [A215582] It has a very long half-life compared to other cephalosporins and is high penetrable into the meninges[A215582], eyes[A215647], and inner ear[A215627].
Products: NOVOSEF 1 G/10 ML IV ENJEKSİYONLUK TOZ VE ÇÖZÜCÜ, 1 ADET, NOVOSEF 1 G/3,5 ML IM ENJEKSİYONLUK TOZ VE ÇÖZÜCÜ, 1 ADET